Cardiovascular Bioengineering (CVBE) Symposium 2023
Abstract Submission Guidelines

Submission Deadline: ~~Tuesday, April 25, 2023, 5:00 PM JST~~
Extended to Friday, April 28, 5:00 PM JST

As you prepare your submission to the meeting, please refer to the following notes and submission requirements:

• To submit abstracts, please fill in a submission form and send it to the congress secretariat for CVBE2023 (cvbe2023@congre.co.jp) via email by the submission deadline.

• All abstracts must be submitted (and if accepted, will be presented) in English with accurate grammar and spelling suitable for publication.

• Authors should not "split" data to create several abstracts from one.

• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.

• Proofread abstracts carefully to avoid errors before the submission deadline.

• Abstract Revisions
  Resending abstracts will be received as abstract revisions by the deadline, April 28, 5:00 PM JST.
  Please note that the latest version is the one with the latest date and time.

Submission Requirements

• Contact Information:
  Provide the full name, institution (including your title), country, and email address for the presenting author on the abstract. The presenting author (presenting author) will receive all future correspondence from CVBE2023 regarding the status of the abstract.

• Abstract Title:
  – An abstract must have a short, specific title (containing no abbreviations or inflammatory language) that indicates the nature of the investigation.

  – The abstract title should not indicate the results of the research that will be presented.

• Abstract Text:
  – Abstracts may have the following identifiable sections: Introduction, Hypothesis, Methods, Results and Conclusions. These fields can be edited or deleted as appropriate your abstract. You may include a hypothesis, but only if it is appropriate to do so.

  – Describe briefly, the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.

- Use generic drug names.

- Do not begin sentences with numerals.

- Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.

- Do not include references, credits, or grant support.

- Do not include the names or personal information of any patient participating in the study or trial.

- Abstracts are limited to 1,950 characters (about 300-350 words). This includes the text plus any graphics, but not the title or authors. All graphics (figures) and text-based graphics (tables) should be provided as 72-300 dpi, pre-sized .gif, .jpg or .tif images only, with a maximum width of 440 pixels (no limit on length).
  Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode. Addition of an image whether a figure or a table deducts 250 characters. Spaces do not count as characters.

• Author Name(s):
 - The submitting author is designated as the primary and presenting author. You may rearrange the order of the authors (during the submission period); however, always list the senior author last. The presenting author does not have to be listed as primary; the presenting author must be listed on the abstract and can be listed anywhere in the author block.

 - Please review the author block carefully. Edits cannot be made after the April 28, 5:00 PM JST deadline. Additions or deletions of author names are not permitted after the submission deadline.

Inquiry